Adding Docetaxel to ADT for High-Risk Nonmetastatic Prostate Cancer: Does It Help?

Researchers tested the combination of docetaxel and ADT in a phase III randomized trial of patients with high-risk nonmetastatic prostate cancer.

Source: CancerNetwork - March 8, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news